<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Modus Therapeutics Holding Ab — News on 6ix</title>
<link>https://6ix.com/company/modus-therapeutics-holding-ab-1</link>
<description>Latest news and press releases for Modus Therapeutics Holding Ab on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 14 Nov 2025 07:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/modus-therapeutics-holding-ab-1" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d56ccbbeedb30cb6f83a27.webp</url>
<title>Modus Therapeutics Holding Ab</title>
<link>https://6ix.com/company/modus-therapeutics-holding-ab-1</link>
</image>
<item>
<title>Interim Report - January-September 2025</title>
<link>https://6ix.com/company/modus-therapeutics-holding-ab-1/news/interim-report-january-september-2025-7</link>
<guid isPermaLink="true">https://6ix.com/company/modus-therapeutics-holding-ab-1/news/interim-report-january-september-2025-7</guid>
<pubDate>Fri, 14 Nov 2025 07:00:00 GMT</pubDate>
<description>STOCKHOLM – 14 November 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report January-September 2025. The full report is available on the Company's website. “We are now approaching a period during which several portfolio companies will conclude their clinical studies, yielding exciting data readouts”, says Viktor Drvota, CEO, Karolinska Development. Significant events during the third quarter Karolinska Development announced an update from Organon on the dev</description>
</item>
<item>
<title>Karolinska Development's portfolio company Modus Therapeutics receives approval for second part of phase 2 study in chronic kidney disease with anemia</title>
<link>https://6ix.com/company/modus-therapeutics-holding-ab-1/news/karolinska-developments-portfolio-company-modus-therapeutics-receives-approval-for-second-part-of-phase-2-study-in-chronic-kidney-disease-with-anemia-2</link>
<guid isPermaLink="true">https://6ix.com/company/modus-therapeutics-holding-ab-1/news/karolinska-developments-portfolio-company-modus-therapeutics-receives-approval-for-second-part-of-phase-2-study-in-chronic-kidney-disease-with-anemia-2</guid>
<pubDate>Tue, 04 Nov 2025 07:45:00 GMT</pubDate>
<description>STOCKHOLM, SWEDEN November 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has received regulatory approval to initiate the second part of the phase 2 study with sevuparin as a treatment of chronic kidney disease with anemia. The study will be initiated in Q4 2025, in line with the company’s development timeline. Modus Therapeutics, listed on Nasdaq First North Growth Market, has received approval from regulatory authori</description>
</item>
<item>
<title>Neumirna Therapeutics Appoints Ellen K. Donnelly as Chief Executive Officer</title>
<link>https://6ix.com/company/modus-therapeutics-holding-ab-1/news/neumirna-therapeutics-appoints-ellen-k-donnelly-as-chief-executive-officer-3</link>
<guid isPermaLink="true">https://6ix.com/company/modus-therapeutics-holding-ab-1/news/neumirna-therapeutics-appoints-ellen-k-donnelly-as-chief-executive-officer-3</guid>
<pubDate>Thu, 18 Sep 2025 09:00:00 GMT</pubDate>
<description>COPENHAGEN, Denmark, September 18, 2025--Neumirna Therapeutics, a biotechnology company developing RNA-based therapies for neurological diseases, today announced the appointment of Ellen K. Donnelly, Ph.D. as Chief Executive Officer.</description>
</item>
<item>
<title>Karolinska Development's portfolio company Modus Therapeutics raises SEK 28.3 million in oversubscribed unit issue</title>
<link>https://6ix.com/company/modus-therapeutics-holding-ab-1/news/karolinska-developments-portfolio-company-modus-therapeutics-raises-sek-283-million-in-oversubscribed-unit-issue-2</link>
<guid isPermaLink="true">https://6ix.com/company/modus-therapeutics-holding-ab-1/news/karolinska-developments-portfolio-company-modus-therapeutics-raises-sek-283-million-in-oversubscribed-unit-issue-2</guid>
<pubDate>Thu, 28 Aug 2025 11:50:00 GMT</pubDate>
<description>STOCKHOLM, SWEDEN August 28, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has raised SEK 28.3 million in a unit issue with a subscription rate of 189 percent. The proceeds from the rights issue are intended to finance the continued development of the drug candidate, sevuparin, for the treatment of chronic kidney disease. Modus Therapeutics, listed on Nasdaq First North Growth Market, has successfully carried out a unit i</description>
</item>
<item>
<title>Karolinska Development's portfolio company Modus Therapeutics completes enrollment in part 1 of its phase 2a study with sevuparin</title>
<link>https://6ix.com/company/modus-therapeutics-holding-ab-1/news/karolinska-developments-portfolio-company-modus-therapeutics-completes-enrollment-in-part-1-of-its-phase-2a-study-with-sevuparin-2</link>
<guid isPermaLink="true">https://6ix.com/company/modus-therapeutics-holding-ab-1/news/karolinska-developments-portfolio-company-modus-therapeutics-completes-enrollment-in-part-1-of-its-phase-2a-study-with-sevuparin-2</guid>
<pubDate>Mon, 14 Jul 2025 06:00:00 GMT</pubDate>
<description>STOCKHOLM, SWEDEN July 14, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Modus Therapeutics has completed patient enrollment on schedule to part 1 of its ongoing clinical phase 2a study with sevuparin, which is being evaluated as a treatment for patients with chronic kidney disease with anemia. Modus Therapeutics, listed on Nasdaq First North Growth Market, has successfully completed the patient enrollment for the initial part of its clinical</description>
</item>
<item>
<title>Karolinska Development's portfolio company Modus Therapeutics carries out a fully secured rights issue of SEK 28.3 million</title>
<link>https://6ix.com/company/modus-therapeutics-holding-ab-1/news/karolinska-developments-portfolio-company-modus-therapeutics-carries-out-a-fully-secured-rights-issue-of-sek-283-million-2</link>
<guid isPermaLink="true">https://6ix.com/company/modus-therapeutics-holding-ab-1/news/karolinska-developments-portfolio-company-modus-therapeutics-carries-out-a-fully-secured-rights-issue-of-sek-283-million-2</guid>
<pubDate>Fri, 27 Jun 2025 14:49:00 GMT</pubDate>
<description>STOCKHOLM, SWEDEN June 27, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics carries out a fully secured rights issue of units of SEK 28.3 million. The proceeds from the rights issue are intended to finance the continued development of the drug candidate sevuparin in chronic kidney disease with anemia. On June 26 2025, the portfolio company Modus Therapeutics, listed on Nasdaq First North Growth Market, announced that the comp</description>
</item>
</channel>
</rss>